Vapor
The US International Trade Commission will launch an investigation
into Apple over potential infringement of electrocardiogram (ECG)
patents by Apple.
This decision was prompted by a complaint filed
by AliveCor on April 20, 2021, which alleges that Apple violated
Section 337 of the Tariff Act through the import and sale of Apple
Watches that the company alleges infringes on its patents.
In the complaint, AliveCor requests that the USITC issues a limited exclusion order and a cease and desist order.
AliveCor
was the first company to launch an ECG device, named the KardiaBand,
which added heart-monitoring functionality to earlier Apple Watch models
prior to the introduction of the Apple Watch Series 4, which featured
built-in ECG monitoring.
AliveCor complaint
AliveCor
alleges in the complaint that Apple infringed three of its ECG patents.
Upon filing the company claimed that this “is one step, among others,
AliveCor is taking to obtain relief for Apple’s intentional copying of
AliveCor’s patented technology”.
In an announcement on AliveCor’s
website, Apple had sought to “eliminate AliveCor as competition” in the
heart rate analysis market by including the ability to take an ECG
reading and perform analysis in the Apple Watch Series 4.
“AliveCor
has invested heavily in bringing advanced, AI-powered cardiological
detection technology to consumer users,” the company claimed.
AliveCor is being represented by Quinn Emanuel Urquhart & Sullivan.
Source:www.worldipreview.com
Author:Alex Baldwin
Editor:IPRdaily-Vapor